MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fyfe, J. A.
Right arrow Articles by Keller, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fyfe, J. A.
Right arrow Articles by Keller, P. M.

Altered thymidine-thymidylate kinases from strains of herpes simplex virus with modified drug sensitivities to acyclovir and (E)-5-(2- bromovinyl)-2'-deoxyuridine

JA Fyfe, SA McKee and PM Keller

Virus-coded thymidine (dThd) kinases were purified by affinity chromatography from a parental strain (SC16) and two strains (SC16 B3 and SC16 S1) of herpes simplex virus, Type 1, with altered drug sensitivities. These latter two strains were less sensitive, respectively, to E-5-(2-bromovinyl)-2'-deoxyuridine (BrVdUrd) and to both BrVdUrd and 9-(2-hydroxyethoxymethyl)guanine (acyclovir). The enzymes were characterized with respect to physical and catalytic properties. The enzyme from SC16 B3 was very similar to the parental enzyme except in its substrate specificity and kinetic constants. It catalyzed the phosphorylation of BrVdUrd at a relative rate that was 110% of the rate with dThd versus a relative rate of 140% with the parental enzyme. The apparent Km value for BrVdUrd was 6 microM versus 0.1 microM for the parental enzyme. The reaction kinetics with acyclovir were similar for the two enzymes. The SC16 B3 enzyme catalyzed the phosphorylation of dTMP, but at only 2% the efficiency of the parental enzyme; phosphorylation of the monophosphate of BrVdUrd (BrVdUMP) was not detected with the SC16 B3 enzyme. The enzyme from the SC16 S1 variant had a much narrower phosphate acceptor specificity than the enzyme from the parental virus. BrVdUrd was a substrate but with a relative rate of 30% and an apparent Km value of 4 microM; acyclovir was neither detectably phosphorylated nor a good inhibitor. BrVdUMP was not detectably phosphorylated. The relative efficiencies of the two variant enzymes for acyclovir phosphorylation correlated well with the sensitivities of the viruses to this compound. In contrast, the relative efficiencies of the second phosphorylation step (BrVdUMP to BrVdUDP) were most consistent with the sensitivities of the viruses to BrVdUrd.

Volume 24, Issue 2, pp. 316-323, 09/01/1983
Copyright © 1983 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
B. D. Pilger, R. Perozzo, F. Alber, C. Wurth, G. Folkers, and L. Scapozza
Substrate Diversity of Herpes Simplex Virus Thymidine Kinase. IMPACT OF THE KINEMATICS OF THE ENZYME
J. Biol. Chem., November 5, 1999; 274(45): 31967 - 31973.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E.-M. Westphal, A. Mauser, J. Swenson, M. G. Davis, C. L. Talarico, and S. C. Kenney
Induction of Lytic Epstein-Barr Virus (EBV) Infection in EBV-associated Malignancies Using Adenovirus Vectors in Vitro and in Vivo
Cancer Res., April 1, 1999; 59(7): 1485 - 1491.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
R. G. Kost, E. L. Hill, M. Tigges, and S. E. Straus
Recurrent Acyclovir-Resistant Genital Herpes in an Immunocompetent Patient
N. Engl. J. Med., December 9, 1993; 329(24): 1777 - 1782.
[Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1983 by the American Society for Pharmacology and Experimental Therapeutics